JPRN-jRCT1012220032招募中Unknown
The efficacy of TEG6s as the management of anticoagulation therapy during pediatric ECMO
Sakai Wataru0 个研究点目标入组 34 人开始时间: 2022年12月26日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 <= 10age old（—）
- 性别
- All
入选标准
- •children less than 10 years old, who require ECMO
排除标准
- •crinical confounder including extereme low birth weigh or ECMO device failure etc
研究者
相似试验
暂停
1 期
Evaluation of Safety and Efficacy of T1h (anti-CD6) as Monotherapy and in Combination with Methotrexate in Patientes with Rheumatoid ArthritisArthritis, RheumatoidArthritisRheumatic DiseasesJoint DiseasesMusculoskeletal DiseasesConnective Tissue DiseasesAutoimmune DiseasesAutoimmune System DiseasesRheumatoid ArthritisRPCEC00000035Center of Molecular Immunology (CIM)
招募中
不适用
The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosisRelapsing-remitting multiple sclerosisJPRN-UMIN000012705Department of Immunology, National Institute of Neuroscience, NCNP10
进行中（未招募）
1 期
A research study looking at how a factor VIII medicine called turoctocog alfa pegol (N8-GP) works in people with haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2017-003788-36-HUovo Nordisk A/S170
进行中（未招募）
1 期
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2013-004025-88-BGovo Nordisk A/S125
进行中（未招募）
1 期
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2013-004025-88-GRovo Nordisk A/S125